<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002248</url>
  </required_header>
  <id_info>
    <org_study_id>081A</org_study_id>
    <secondary_id>UNX-4101</secondary_id>
    <nct_id>NCT00002248</nct_id>
  </id_info>
  <brief_title>A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients</brief_title>
  <official_title>A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Univax Biologics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      PRIMARY: To assess the effect of bovine anti-Cryptosporidium immunoglobulin (BACI) on the&#xD;
      volume of diarrhea due to Cryptosporidium parvum in AIDS patients who have protracted&#xD;
      Cryptosporidium enteritis.&#xD;
&#xD;
      SECONDARY: To assess changes in stool consistency and frequency, body weight, and safety in&#xD;
      this patient population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Forty patients are randomized to receive either BACI or placebo (bovine colostrum from&#xD;
      non-immunized cattle) for 1 week. The double-blind portion of the study will be followed by&#xD;
      an open-label phase in which all 40 patients receive BACI for 1 week.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>40</enrollment>
  <condition>Cryptosporidiosis</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cryptosporidium Immune Whey Protein Concentrate (Bovine)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Antidiarrheal compounds (if dose remains stable).&#xD;
&#xD;
          -  Zidovudine (AZT), dideoxyinosine (ddI), dideoxycytidine (ddC), or alternative HIV&#xD;
             therapy (provided dose was stable for at least 4 weeks prior to study entry).&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  AIDS.&#xD;
&#xD;
          -  Cryptosporidium parvum enteritis.&#xD;
&#xD;
          -  Chronic diarrhea.&#xD;
&#xD;
          -  Life expectancy of at least 4 weeks.&#xD;
&#xD;
          -  Ability to tolerate food by mouth.&#xD;
&#xD;
          -  Ability to take the histamine H2-receptor antagonist famotidine (Pepcid).&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Antidiarrheal compounds (provided dose has remained stable in the 7 days prior to&#xD;
             study entry).&#xD;
&#xD;
          -  Zidovudine (AZT), dideoxyinosine (ddI), dideoxycytidine (ddC), or alternative HIV&#xD;
             therapy (provided dose has remained stable for at least 4 weeks prior to study entry).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Concurrent unresolved clinical infections with enteric pathogens other than C. parvum&#xD;
             (e.g., rotavirus, Salmonella, Shigella, Campylobacter, Giardia, C. difficile toxin,&#xD;
             Yersinia, amebiasis, MAI, CMV, Microsporida) as determined by history or routine&#xD;
             microbiology screening.&#xD;
&#xD;
          -  Other acute infections or concurrent immediately life-threatening medical crisis other&#xD;
             than cryptosporidiosis.&#xD;
&#xD;
          -  Grossly bloody diarrhea.&#xD;
&#xD;
          -  Known allergy to milk or milk products (other than lactose intolerance).&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Other experimental therapy (e.g., macrolide antibiotics, paromomycin) within 30 days&#xD;
             prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gabin Med Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF - San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Consortium of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Med Ctr</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Elizabeth's Hosp</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nord J, Ma P, Tacket CO, Dijohn D, Tzipori S, Sahner D, Shieb G. Treatment of AIDS associated cryptosporidiosis with hyperimmune colostrum from cows vaccinated with cryptosporidium. Int Conf AIDS. 1989 Jun 4-9;5:656 (abstract no C586)</citation>
  </reference>
  <verification_date>April 1993</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Antidiarrheals</keyword>
  <keyword>Cryptosporidiosis</keyword>
  <keyword>Diarrhea</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Cryptosporidium</keyword>
  <keyword>Immunization, Passive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cryptosporidiosis</mesh_term>
    <mesh_term>Enteritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

